Form 4: Amarin CSO Ketchum Reports RSU Vesting, New Equity Grants

Amarin's EVP and Chief Scientific Officer, Steven B. Ketchum, reported the vesting of restricted stock units and new equity awards, including RSUs and stock options.

Summary

• Steven B. Ketchum, EVP, Chief Scientific Officer of Amarin Corp PLC, reported transactions related to his equity compensation.
• On January 31, 2026, 2,246 American Depositary Shares (ADS) vested from a February 21, 2023 RSU grant.
• Concurrently, 1,235 ADS were disposed of at $15.42 to cover tax liabilities related to this vesting.
• Also on January 31, 2026, 1,933 ADS vested from a February 1, 2024 RSU grant.
• An additional 1,062 ADS were disposed of at $15.42 for tax withholding related to this second vesting event.
• Following these transactions, Ketchum beneficially owns 40,879 non-derivative American Depositary Shares.
• On February 1, 2026, Ketchum was granted 8,013 new Restricted Stock Units (RSUs) under the Amarin Corporation plc 2020 Stock Incentive Plan. These RSUs will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029.
• Additionally, on February 1, 2026, he received an option to purchase 36,060 ADSs at an exercise price of $14.99. This option vests over three years, with 33% vesting on February 1, 2027, and the remainder vesting ratably over the subsequent eight calendar quarters. The option expires on February 1, 2036.
• An ADS ratio change became effective on April 11, 2025, where one ADS now represents twenty Ordinary Shares, and all reported amounts reflect this adjustment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. It reflects routine executive compensation activities, including vesting and new grants, which are standard for retaining key talent and aligning interests, without indicating any immediate operational or financial changes.

Positives

• The EVP, Chief Scientific Officer received new equity grants (8,013 RSUs and options for 36,060 ADSs), indicating continued long-term incentive alignment with shareholder interests.
• Vesting of previously granted RSUs demonstrates the company's commitment to its executive compensation plan.

Negatives

• Disposition of 2,297 ADSs (1,235 + 1,062) at $15.42 for tax withholding purposes, while standard, represents a reduction in direct beneficial ownership from the vested shares.

Future Outlook

The filing indicates future vesting events for existing and newly granted equity awards. The 8,013 RSUs granted on February 1, 2026, will vest in equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. The option to purchase 36,060 ADSs granted on February 1, 2026, will vest 33% on February 1, 2027, with the remainder vesting ratably over the subsequent eight calendar quarters.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) and stock options to key executives like the Chief Scientific Officer is a standard practice in the biotechnology and pharmaceutical industry. This compensation structure aims to align executive incentives with long-term shareholder value creation, particularly in companies like Amarin, which rely heavily on scientific innovation and product development. The vesting schedules encourage retention and sustained performance.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical and biotech sectors frequently include a significant equity component, such as RSUs and stock options, similar to Amarin's approach.
• Companies like Pfizer, Johnson & Johnson, and Moderna also utilize multi-year vesting schedules for equity awards to retain talent and incentivize long-term performance. For instance, Moderna's executive compensation often includes performance-based RSUs and stock options with vesting periods extending over several years.
• The ADS ratio change is a corporate action that can impact liquidity and trading dynamics, a practice seen in other international companies with U.S. listings, such as AstraZeneca or GSK, though the specific ratio change is company-specific.

Stakeholder Impact

• Shareholders: The new equity grants align executive incentives with long-term shareholder value. Tax-related dispositions are a normal part of executive compensation. The ADS ratio change impacts how shares are represented but not the underlying value.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Future vesting of 1,933 RSUs (from 2024 grant) on January 31, 2027.
• Future vesting of 8,013 RSUs (from 2026 grant) in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029.
• Future vesting of 36,060 stock options (from 2026 grant) with 33% on February 1, 2027, and the remainder ratably over the subsequent eight calendar quarters.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including RSU vesting, tax-related share dispositions, and new equity grants. These are standard events for a publicly traded company and do not provide new information that would significantly alter the fundamental investment thesis for Amarin. The transactions reflect ongoing executive incentive alignment rather than a change in company performance or outlook, thus warranting a "hold" recommendation based solely on this filing.

Keywords

Amarin, AMRN, Steven B. Ketchum, SEC Form 4, insider transaction, RSU, restricted stock unit, stock option, equity grant, executive compensation, beneficial ownership, ADS, American Depositary Shares